DYRK1A and leukemia: This is particularly relevant for B- and T-cells, where dysregulation of DYRK1A–i.e., due to T21– may underly important pathogenic outcomes associated with DS, such as uncontrolled (auto-) inflammatory conditions or leukemia (see next sections).